Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study

NCT01900015 is registered in ClinicalTrials.gov with Juan Macías as lead sponsor.

NCT NCT01900015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01900015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study
Lead sponsor
Juan Macías
Phase
Phase 4
Overall status
Completed
Start date
February 3, 2014
Completion date
January 17, 2017
Enrollment
45 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hcv coinfection, hiv infection